However, an accommodating combination of rituximab, erythropoietin or C1s-antibody (sutimlimab® (23) and in cases of severe life-threatening hemolysis C5-antibody (eculizumab®) may be beneficial in patients with difficult to control CAD. This evidence concerns the gene EPO and cold agglutinin disease.